A commercial weight management program paired with continuous glucose monitoring significantly reduced body weight at 6 months (MD -3.2%; 95% CI -5.0 to -1.4%) compared to usual care.
RCT (n=151)
two-arm
Yes
Does a commercial weight management program integrated with continuous glucose monitoring improve weight loss and glycemic control in adults with type 2 diabetes?
A commercial weight management program paired with continuous glucose monitoring provided significantly greater weight loss over 12 months and HbA1c reduction at 6 months compared to usual care in patients with T2DM.
Mean Difference: -3.2 (95% CI -5–-1.4)
Introduction and Objective: Commercial weight management programs have been shown to be effective in adults, with additional improvements in glycemic control. Continuous glucose monitoring (CGM) has emerged as an effective tool to track glucose levels and provide feedback to support behavior change. The objective was to test the effectiveness of integrating CGM into a behavioral weight management program to improve weight loss and glycemic control among adults with T2DM. Methods: We conducted a two-arm, three-site, randomized controlled trial of a commercial weight management program (INT, WeightWatchers Diabetes Program) integrated with CGM (Abbott FreeStyle Libre 2) compared to usual care (UC) in patients with T2DM. Outcomes included 6- and 12-month changes in HbA1c and body weight. Data were analyzed using repeated measures mixed models employing the intention-to-treat principle. Results: At baseline, the sample included 151 participants (67.6% female) with a mean (± SD) age of 54.7 ± 9.1 years, BMI of 35.2 ± 6.9 kg/m2, and HbA1c of 8.6% ± 1.0%, with diverse race and ethnicity (12% Hispanic, 19.3% Non-Hispanic Black, 23.3% Non-Hispanic Asian, 41.3% Non-Hispanic White, 4% Multiracial/Other). Retention in the study was 79.5% at 6 months and 73.5% at 12 months. Percent change in body weight after 6 and 12 months was significantly greater in INT compared to UC, with a mean difference of -3.2% (95% Confidence Interval: -5.0 to -1.4%) at 6 months and -2.6% (-4.5 to -0.8%) at 12 months. Participants in INT also reduced HbA1c more than UC at 6 months (mean difference: -0.46%; -0.90 to -0.02%), with a non-statistically significant difference of -0.34% (-0.80 to 0.12%) at 12 months. Conclusion: A widely available digital, commercial weight management program paired with CGMs provided significantly greater improvements in weight loss over 6 and 12 months with significantly greater reduction in HbA1c at 6 months compared to usual care in patients with T2DM. Disclosure P. Katzmarzyk: Research Support; Current; WW International, Inc. K. Drews: None. J. Ard: Consultant; Current; Novo Nordisk, Eli Lilly and Company, Amgen Inc., Roche Pharmaceuticals, Viking Therapeutics, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Zealand Pharma A/S. Research Support; Current; Weight Watchers. Consultant; Current; Epitomee. T. McLaughlin: Research Support; Ended; Lilly. Advisory Panel; Ended; Regeneron Pharmaceuticals Inc. Research Support; Current; Recordati S.p.A. Stock/Shareholder; Current; January, Inc. Research Support; Current; WW International, Inc. Consultant; Ended; Eiger BioPharmaceuticals. Advisory Panel; Current; Amylyx. Consultant; Current; Oura. Research Support; Current; Dexcom, Inc. M.N. Harris: Consultant; Current; WW International, Inc. A.M. Lee: Employee; Current; Eli Lilly and Company. Employee; Ended; WW International, Inc. Consultant; Ended; WW International, Inc. G. Foster: Consultant; Current; WW International, Inc., Abbott. H. Lee: Employee; Current; Abbott. T. Dunn: Employee; Current; Abbott Diabetes. C. Martin: Advisory Panel; Current; Wondr Health. Other - I received royalties from my institution that originate from a licensing agreement with ABGIL.; Ended; ABGIL. Other - I attended a single Experts Insights Meeting.; Current; Almond Board. Other - I presented and attended a single Advisory Board meeting and Panel Discussion.; Current; Medifast. Consultant; Ended; Zealand Pharma A/S. Research Support; Ended; Spoonified. Research Support; Current; Foundation for Food and Agriculture Research; Kroger Co. Zero Hunger / Zero Waste Foundation. Research Support; Ended; WW International, Inc., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk. F.L. Greenway: Advisory Panel; Current; Vitakey, GATC Health, Biohaven. Consultant; Current; NovMeta Pharmaa. Advisory Panel; Current; Uplifting Results Laboratory (UR Labs). Consultant; Current; Ketogenic Health Systems, Energesis Pharmaceutical Company, Regenerate Bio, Slim Helath Nutrition. Advisory Panel; Current; Neurocrine Biosciences, Inc. Stock/Shareholder; Current; Ilerabio, Verdant Health. Consultant; Current; Currax, Pep19. Advisory Panel; Current; Rivas Pharmaceuticals. Consultant; Ended; Lumen Bioscience, Inc. Advisory Panel; Ended; Altimmune. Consultant; Ended; Dexcom, Inc. Advisory Panel; Ended; Nusirt Sciences. Consultant; Ended; General Nutrition Corporation, Plensat Inc., Melior Discoveries, Academic Technology Ventures, Inc. Advisory Panel; Ended; Nutraceutical Corporation, Gelesis. Consultant; Ended; Well Cell Global. M. Cardel: Employee; Current; WW International, Inc. Stock/Shareholder; Current; WW International, Inc. Funding WW International; Abbott
Katzmarzyk et al. (Fri,) conducted a rct in Type 2 Diabetes (n=151). WeightWatchers Diabetes Program integrated with continuous glucose monitoring vs. Usual care was evaluated on Percent change in body weight at 6 months (MD -3.2%, 95% CI -5.0 to -1.4). A commercial weight management program paired with continuous glucose monitoring significantly reduced body weight at 6 months (MD -3.2%; 95% CI -5.0 to -1.4%) compared to usual care.